Interviews

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic strategies for this aggressive disease.

Andrew Jallouk, MD, highlights the challenges in lymphoma treatment, including access disparities and the need for personalized therapies for better patient outcomes.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Hardeep Phull, MD, explains the impact that telehealth has had for oncologists and patients.

A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.

Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment and patient care.

A recent trial reveals cemiplimab significantly reduces recurrence in high-risk cutaneous squamous cell carcinoma, setting a new standard for adjuvant treatment.

New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.

A groundbreaking clinical trial explores botensilimab/balstilimab combination therapy, offering new hope for advanced colorectal cancer patients lacking effective immunotherapy options.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.

Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.

George Mulligan, PhD, highlights the importance of clinical trials and innovative research in advancing myeloma treatment and pursuing potential cures.

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

George Mulligan, PhD, explores the impact of linvoseltamab's FDA approval on multiple myeloma treatment, highlighting innovative bispecific antibodies and patient-centered strategies.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.

Researchers explore TAF1's role in leukemia, revealing potential targeted therapies that could transform treatment approaches for acute myeloid leukemia.

Study reveals alarming treatment gaps in high-risk Myelodysplastic Syndromes, highlighting disparities and adherence issues that impact patient outcomes.

A recent study uncovers disparities in treatment patterns for myelodysplastic syndromes, revealing critical insights into patient outcomes and care access.

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of Chief Insights in Oncology.

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating CAR T toxicities.